SEC 13F Intelligence

Dafna Capital Management LLC / NKTR

Dafna Capital Management LLC’s Nektar Therapeutics Position

Does Dafna Capital Management LLC own Nektar Therapeutics (NKTR)? Yes — 165.2K shares worth $12M (+2.70% of its 13F portfolio) as of Q1 2026, up from 75.0K shares the prior filed quarter.

Position Value
$12M
Q1 2026
Shares
165.2K
% of Portfolio
+2.70%
Quarters Held
4
currently held

Position History NKTR

Reported value by quarter
Q2 ’25: $258,400Q2 ’25Q3 ’25: $3MQ3 ’25Q4 ’25: $3MQ4 ’25Q1 ’26: $12MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026165.2K$12M+2.70%
Q4 202575.0K$3M+0.74%
Q3 202555.0K$3M+0.77%
Q2 202510.0K$258,400+0.07%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Dafna Capital Management LLC’s full portfolio or all institutional holders of NKTR.